ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MVA-BN-EBV

Its studies are mostly in Epstein-Barr Virus Infections, led by Bavarian Nordic.

Furthest: phase 1, since Oct 15, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bavarian Nordic11 open or runningphase 1since Oct 15, 2026Oct 15, 2026Dec 31, 2027phase 1 · NCT07888088

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2026First study: phase 1 study in Epstein-Barr Virus InfectionsFirst studyNCT07888088 · 15 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Epstein-Barr Virus InfectionsNCT07888088

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07888088Epstein-Barr Virus Infections · United States1Not yet recruitingDec 31, 202715

How it is read

Names in the registry

  • “MVA-BN-EBV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.